In the clinic, in vivo activity of CYP enzymes is most commonly predicted from an individual’s genotype, which underestimates the potential effects of a host of other factors, including inhibition of CYP expression and activity by increased levels of circulating inflammatory cytokines during chemotherapy for breast cancer. Here, PPIG is linked to breast carcinoma.